Written By: Pharmacally Medical News Desk
Dupixent® (Dupilumab), developed by Regeneron Pharmaceuticals, has been honored with the prestigious 2025 Prix Galien USA Award for Best Biotechnology Product. This accolade recognizes Dupixent as a groundbreaking scientific innovation that has transformed the management of multiple allergic and atopic conditions worldwide. At the same time Gilead’s Yeztugo was honored with best pharmaceutical product by Prix Galien USA.
The Prix Galien USA Awards, often regarded as the Nobel Prize of the pharmaceutical industry, celebrate extraordinary advancements that significantly improve human health. Dupixent receipt of this award underscores its unique position as the first and only therapy that specifically targets the interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways key drivers of type 2 inflammations underlying a spectrum of serious diseases.
“Dupixent is a true ‘first-in-class’ breakthrough that treats multiple serious diseases and has redefined our understanding of allergic and atopic disorders by showing these often disparate conditions share a common inflammatory mechanism,” said George D. Yancopoulos, M.D., Ph.D., Regeneron’s Board co-Chair, President, Chief Scientific Officer, and principal inventor of Dupixent. “Today, more than 1 million patients worldwide benefit from Dupixent across eight approved indications, with more indications in clinical development.”
Since its FDA approval in 2017, Dupixent has expanded its label to include conditions such as atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, prurigo nodularis, and most recently, chronic obstructive pulmonary disease with an eosinophilic phenotype (approved 2024). Its innovative mechanism and robust clinical trial data have led to widespread adoption, making it a pillar in treating type 2 inflammatory diseases.
The award ceremony held in New York City marked Regeneron’s second “Best Biotechnology Product” win, previously receiving this honor for Inmazeb® in 2022. Dupixent’s recognition highlights not only scientific and clinical excellence but also its profound impact on patient care and public health globally.
With ongoing research and additional indications in pipeline development, Dupixent continues to lead as a transformational therapy in biotechnology. This prestigious Prix Galien award cements its status as a milestone in modern medicine’s fight against complex allergic and inflammatory diseases.
References
Dupixent® (dupilumab) wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award, Regeneron, 31 Oct 2025, https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-wins-prestigious-2025-prix-galien-usa-best
Market Screener: Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award, https://www.marketscreener.com/news/dupixent-dupilumab-wins-prestigious-2025-prix-galien-usa-best-biotechnology-product-award-ce7d5cdbdf8dff21
Santelog: Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award, https://www.santelog.com/actualites-sante-nasdaq/dupixentr-dupilumab-wins-prestigious-2025-prix-galien-usa-best-biotechnology
Dupixent, Prescribing Information, https://www.regeneron.com/downloads/dupixent_fpi.pdf